As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

Eli Lilly & Co.’s diabetes and weight-loss drugs Mounjaro and Zepbound are no longer in short supply in the US, which means ...

Novo Nordisk stock fell sharply early Friday after the pharmaceutical giant, known for its blockbuster drugs Ozempic and ...

Eli Lilly just gave investors several reasons to cheer.

The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...

Eli Lilly, the pharma giant behind the popular weight-loss drug Zepbound, said it plans to test obesity medications as a ...

Novo Nordisk’s stock dives as new weight loss drug disappoints in a late-stage trial, which gave a boost to Eli Lilly shares.

"An MDL that encompassed any potential injury relating to use of these exceedingly popular weight loss drugs might quickly ...

Nestle just rolled out a new protein shot drink that it says will help people looking to lose weight manage their hunger and ...

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly ...